Oncology Drugs - Japan | Statista Market Forecast

The projected revenue for the Oncology Drugs market in Japan is expected to reach ¥US$8.11bn in 2024.
This indicates a promising growth potential for the country's oncology drugs industry.
Furthermore, it is anticipated that the market will experience a steady annual growth rate (CAGR 2024-2029) of 6.75%, leading to a market volume of ¥US$11.24bn by 2029.
When compared globally, it is noteworthy that United States is projected to generate the highest revenue in the oncology drugs market, with an estimated value of US$103.90bn in 2024.
This highlights the dominant position of the United States in the global oncology drugs market.
Japan is at the forefront of innovative oncology drug research and development, striving to improve patient outcomes and revolutionize cancer treatment.

Definition:
The Oncology Drugs market covers drugs to treat cancer, including chemotherapy and immunotherapy. These therapies are used for solid tumors and hematologic cancer. The medications in this market are mainly physician-administered drugs.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol-Myers Squibb, Roche, Merck & Co, Novartis, Johnson & Johnson

Treatment for different types of cancer, including skin cancer, leukemia, lymphoma, and multiple myeloma
Chemotherapeutic agents
Immuno-oncology drugs
Oncology orphan drugs

Radiation therapy
Medical devices

The Oncology Drugs market in Japan has experienced significant growth in recent years.

Customer preferences: Cancer is one of the leading causes of death in Japan, and as such, demand for oncology drugs has been on the rise. Patients in Japan prefer to receive the latest and most advanced treatments available, which has driven demand for innovative oncology drugs.

Trends in the market: The Oncology Drugs market in Japan has seen a shift towards targeted therapies and immunotherapies. This trend is driven by the desire to provide more personalized treatment options for patients. Additionally, the Japanese government has implemented policies to accelerate the approval process for oncology drugs, which has led to an increase in the number of drugs available on the market.

Local special circumstances: Japan has an aging population, which has contributed to the high incidence of cancer in the country. Additionally, Japan has a well-developed healthcare system that provides universal coverage, which has made it easier for patients to access oncology treatments. The Japanese government has also implemented policies to promote the development of new oncology drugs, which has created a favorable environment for drug manufacturers.

Underlying macroeconomic factors: Japan is the third-largest economy in the world and has a high standard of living. The country has a well-developed healthcare system and invests heavily in research and development. These factors have contributed to the growth of the Oncology Drugs market in Japan. Additionally, the Japanese government has implemented policies to promote innovation in the pharmaceutical industry, which has created a favorable environment for drug manufacturers.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Cancer is one of the leading causes of death worldwide, with lung cancer alone ranked the sixth leading cause of death in 2021. Cancer, also known as malignant tumors and neoplasms, is the result of interactions between personal genetic factors and external agents causing abnormal transformations of cells into tumors over time. As the global population has increased in age, the incidence of new cancer cases has also risen, contributing to a higher number of deaths each year. In 2022, nearly 10 million deaths were caused by cancer worldwide- a number which is expected to reach over 15 million by 2040.